Thoracic Cancer Clinical Trials

13 trials identified.

CALGB 30610 (Limited Small Cell Lung Cancer)
Principal Investigator: Crawford, Jeffrey
Protocol Number: PRO00007332

Age Group: Adult
Scope: National

Phase: III (Cancer Control)
Disease Site: Lung

Contact: Allen, Donna
Phone:

What is the Condition Being Studied?
Limited-stage small cell lung cancer
What is the Purpose of this Study?
We are doing this study to compare two different ways to give radiation therapy to see which way is better for patients with small cell lung cancer on standard chemotherapy.
Who Can Participate in the Study?
Adults with small cell lung cancer who:
- Have not had any radiotherapy 
- Have had no more than 1 cycle of chemotherapy
- Have not had surgery to completely remove the lung cancer    
- Are not pregnant or nursing 
What is Involved?
If you choose to join this study, you will:
- Be randomized (like a flip of a coin) to get either: 
-- Group 1: The standard amount of radiation therapy twice a day for 3 weeks
-- Group 2: Higher than the standard amount of radiation therapy once a day for 7 weeks  
- Continue to have the recommended amount of chemotherapy for small cell lung cancer  
- Have CT scans for up to 10 years; every 3 months for the first 2 years, every 6 months for the next 3 years, then yearly for the next 5 years  
- Have pulmonary function tests to look at your lung function
Participating Institutions:
  • Duke Cancer Center Cary : Donna Allen
  • Duke Raleigh Hospital : Donna Allen
  • Duke University Health System : Donna Allen
  • Duke Women's Cancer Care Raleigh (Macon Pond) : Donna Allen
View this trial at ClinicalTrials.gov

Alliance A081105: Non-Small Cell Lung Cancer
Principal Investigator: Crawford, Jeffrey
Protocol Number: PRO00057973

Age Group: Adult
Scope: National

Phase: III (Cancer Control)
Disease Site: Lung

Contact: DCI Clinical Research Team, Thoracic Oncology
Email:

What is the Condition Being Studied?
Non-Small Cell Lung Cancer
What is the Purpose of this Study?
We are doing this study to compare the standard treatment with standard treatment plus the study drug erlotinib to see which one is better. 
Who Can Participate in the Study?
Adults with non-small cell lung cancer who:
- Have completely resected non-squamous non-small cell lung cancer
- Have no history of cornea abnormalities
- Are not pregnant or nursing
What is Involved?
If you choose to join this study, you will:
- Be randomized (like the flip of a coin) and get either:
-- Group 1: The study drug erlotinib for up to 2 years 
-- Group 2: Observation; will not get erlotinib but will be followed by their study doctor
-- Get a CT scan and clinic visits every 6 months for the first 4 years and then yearly for the following 6 years for up to 10 years from the start of the study
Participating Institutions:
  • Duke Cancer Center Cary : Thoracic Oncology DCI Clinical Research Team
  • Duke Raleigh Hospital : Thoracic Oncology DCI Clinical Research Team
  • Duke University Health System : Thoracic Oncology DCI Clinical Research Team
  • Duke Women's Cancer Care Raleigh (Macon Pond) : Thoracic Oncology DCI Clinical Research Team
  • Johnston Health (Smithfield) : Thoracic Oncology DCI Clinical Research Team
  • Maria Parham Health (Henderson) : Thoracic Oncology DCI Clinical Research Team
  • Scotland Health Care System (Laurinburg) : Thoracic Oncology DCI Clinical Research Team
  • Southeastern Regional Medical Center (Lumberton) : Thoracic Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

ECOG-ACRIN EA5142 (Non-Small Cell Lung Cancers)
Principal Investigator: Crawford, Jeffrey
Protocol Number: PRO00073268

Age Group: Adult
Scope: National

Phase: III (Cancer Control)
Disease Site: Lung

Contact: DCI Clinical Research Team, Thoracic Oncology
Email:

What is the Condition Being Studied?
Non-Small Cell Lung Cancer
What is the Purpose of this Study?
We are doing this study to find out if adding the study drug Nivolumab will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. 
Who Can Participate in the Study?
Adults with non-small cell lung cancer who:
- Completed surgical resection of non-small cell lung cancer
- Are not pregnant or nursing
- Do not have an autoimmune disease
What is Involved?
If you choose to join this study, you will:
- Be randomized (Like the flip of a coin) to get either:
-- Group 1: The study drug Nivolumab through an IV in your vein once every 4 weeks for up to 1 year
-- Group 2: Observation with the standard postoperative follow-up
- Have follow-up visits every 3 months for the first two years, every 6 months for the net two years, and then once a year for up to ten years from when you began the study
- Have CT scans of the chest every 6 months until you are 4 years from when you started the study and then every 12 months for up to 10 years from the time you started the study
Participating Institutions:
  • Duke Cancer Center Cary : Thoracic Oncology DCI Clinical Research Team
  • Duke Raleigh Hospital : Thoracic Oncology DCI Clinical Research Team
  • Duke University Health System : Thoracic Oncology DCI Clinical Research Team
  • Duke Women's Cancer Care Raleigh (Macon Pond) : Thoracic Oncology DCI Clinical Research Team
  • Johnston Health (Smithfield) : Thoracic Oncology DCI Clinical Research Team
  • Maria Parham Health (Henderson) : Thoracic Oncology DCI Clinical Research Team
  • Scotland Health Care System (Laurinburg) : Thoracic Oncology DCI Clinical Research Team
  • Southeastern Regional Medical Center (Lumberton) : Thoracic Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

ATOMIC ARI-AT-002 for Advanced Non-Small Cell Lung Cancer
Principal Investigator: Stinchcombe, Thomas
Protocol Number: PRO00074492

Age Group: Adult
Scope: National

Phase: II (Cancer Control)
Disease Site: Lung

Contact: DCI Clinical Research Team, Thoracic Oncology
Email:

What is the Condition Being Studied?
Advanced non-small cell lung cancer (NSCLC) 
What is the Purpose of this Study?
We are doing this study to find out if the study drug brigatinib (AP26113) is safe and will work in adults with advanced lung cancer (called non-small cell lung cancer or NSCLC) with ALK rearrangement.
Who Can Participate in the Study?
Adults who have confirmed non-small cell lung cancer with gene mutation
What is Involved?
If you choose to join this study, you will:
- Be given the study drug, brigatinib
-- You will take brigatinib once a day by mouth
- Have blood samples and possibly a small piece of tissue removed from your lung to see what type of lung cancer cells you have
- Have other tests, exams, and procedures for study purposes and your standard of care
- Be in the study for up to 24 months after the start of study drug or until your condition worsens or you have unbearable side effects
Participating Institutions:
  • Duke University Health System : Thoracic Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

BMS-817 (Non-Small Cell Lung Cancer)
Principal Investigator: Ready, Neal
Protocol Number: PRO00075721

Age Group: Adult
Scope: National

Phase: IV (Cancer Control)
Disease Site: Lung

Contact: DCI Clinical Research Team, Thoracic Oncology
Email:

What is the Condition Being Studied?
Non-small cell lung cancer (NSCLC)
What is the Purpose of this Study?
We are doing this study to find out if Nivolumab and Ipilimumab will work for treating lung cancer with high tumor mutation burden.
Who Can Participate in the Study?
Adults who have lung cancer (first-line non-small cell lung cancer) with high tumor mutation burden (TMB)
What is Involved?
If you choose to join this study, you will:
- Get nivolumab 240 mg every 2 weeks and ipilimumab at 1 mg/kg every 6 weeks as long as you are getting better
Participating Institutions:
  • Duke University Health System : Thoracic Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

UM1 9903 AZD9291 + Navitoclax (Non-Small Cell Lung Cancer)
Principal Investigator: Abbruzzese, James
Protocol Number: PRO00082309

Age Group: Adult
Scope: National

Phase: I (Cancer Control)
Disease Site: Lung

Contact: DCI Clinical Research Team, Phase I Clinical Trials Office
Email:

What is the Condition Being Studied?
Metastatic non-small cell lung cancer that has a genetic mutation in the EGFR (epidermal growth factor receptor) gene that has returned after treatment.
What is the Purpose of this Study?
We are doing this study to learn if the two drugs AZD9291 (osimertinib) and navitoclax, are safe if given together in treating non-small cell lung cancer.
Who Can Participate in the Study?
Adults with non-squamous NSCLC, with incurable advanced or metastatic disease 
What is Involved?
If you join this study you will be placed in either group 1 or group 2.  
Each group will receive called an investigational drug combination of AZD9291 and navitoclax once a day by mouth on a 28 day cycle.    
In Group 1:  The first several study participants will receive the lowest dose of the study drugs. 
If the study drugs do not cause serious side effects, the drugs will be given to other participants at higher doses. 
The doses will continue to increase for each subgroup until side effects occur that require the dose to be lowered. 
Once a dose is identified that does not cause serious side effects, the next part of the study will begin.     

In Group 2:  The dose of the study drugs you receive will depend on the best dose identified in the Group 1 part of this study.      

You will receive the study drugs until your cancer grows or until side effects require you to stop. After you finish taking the study drugs, your doctor will continue to watch you for side effects for 30 days.
Participating Institutions:
  • Duke Raleigh Hospital : Phase I Clinical Trials Office DCI Clinical Research Team
  • Duke University Health System : Phase I Clinical Trials Office DCI Clinical Research Team
View this trial at ClinicalTrials.gov

NRG-LU002 (Non-Small Cell Lung Cancer)
Principal Investigator: Stinchcombe, Thomas
Protocol Number: PRO00084715

Age Group: Adult
Scope: National

Phase: II/III (Cancer Control)
Disease Site: Lung

Contact: DCI Clinical Research Team, Thoracic Oncology
Email:

What is the Condition Being Studied?
Non-small cell lung cancer
What is the Purpose of this Study?
We are doing this study to compare using the usual drug therapy plus radiation to treat the lung cancer and areas where the cancer has spread compared with the usual drug therapy alone.
Who Can Participate in the Study?
Adults 18 years of age or older with non-small cell lung cancer who:
- Are not pregnant or nursing
- have measurable disease
- have one site where cancer has spread
What is Involved?
If you agree to be in the study you will:
- Be randomized (put into one of two groups by chance like a flip of a coin) and receive either:
Group 1 - the usual drug regimen alone
Group 2 - radiation to the lung tumor and other areas in the body where the cancer has spread, and possibly undergo surgery, followed by the usual drug regimen.

For both groups, after you stop the usual regimen your doctor will continue to watch you for side effects and follow your condition every 3 months for the first 2 years, every 6 months for the next 3 years, and then yearly afterwards.
Participating Institutions:
  • Duke University Health System : Thoracic Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

Multicenter, Prospective triAL of ELectromagnetIc BroNchoscOpic and ElectromagNEtic Transthoracic Approaches for the Biopsy of Peripheral Pulmonary Nodules (ALL IN ONE)
Principal Investigator: Wahidi, Momen
Protocol Number: PRO00086561

Age Group: Adult
Scope: National

Phase: IV
Disease Site: Lung

Contact: Coles, Kathleen
Phone:

What is the Condition Being Studied?
Lung nodules suspicious for cancer
What is the Purpose of this Study?
We are doing this study to learn about new technologies that may be helpful when looking for nodules during a lung biopsy using computer guided techniques
Who Can Participate in the Study?
- Adult men and women over at 21 who 
- Have a lung nodule that has a good possibility of being lung cancer 
- Are not pregnant
What is Involved?
If you agree to join the study, you will: 
- Have 2 study visits one of which will be a screening visit during which your doctor will review your xrays and medical history 
- Have a bronchoscopy and chest CT scan and possibly a computer guided biopsy
Participating Institutions:
  • Duke University Health System : Kathleen Coles
View this trial at ClinicalTrials.gov

Spectrum SPI-POZ-202 (Non-Small Cell Lung Cancer)
Principal Investigator: Clarke, Jeffrey
Protocol Number: PRO00087877

Age Group: Adult
Scope: National

Phase: II (Cancer Control)
Disease Site: Lung

Contact: DCI Clinical Research Team, Thoracic Oncology
Email:

What is the Condition Being Studied?
Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Exon 20 Insertion Mutation 
What is the Purpose of this Study?
We are doing this study to find out if a study drug poziotinib is safe and effective in treating NSCLC with EGFR or HER2 Exon 20 Insertion Mutation. 
Who Can Participate in the Study?
Adults who have confirmed non-small cell lung cancer with EGFR or HER2 Exon 20 Insertion Mutation.
What is Involved?
Based upon your Exon 20 insertion mutation-positive status (EGFR or HER2), you will be assigned to one of 4 groups and you will:
- Take poziotinib pills (10 or 16 mg) by mouth daily with breakfast at the same time each morning. 
- Have blood samples and possibly a small piece of tissue removed from your lung to see what type of lung cancer cells you have
- Have other tests, exams, and procedures for study purposes and your standard of care.
- Be in the study for up to 24 months after the start of study drug or until your condition worsens or you have intolerable side effects.
Participating Institutions:
  • Duke University Health System : Thoracic Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

TOP 1703: Osimertinib for Patients with Stage 4 Non-Small Cell Lung Cancer
Principal Investigator: Stinchcombe, Thomas
Protocol Number: PRO00088376

Age Group: Adult
Scope: National

Phase: II (Cancer Control)
Disease Site: Lung

Contact: DCI Clinical Research Team, Thoracic Oncology
Email:

What is the Condition Being Studied?
Non-Small Cell Lung Cancer (NSCLC) 
What is the Purpose of this Study?
We are doing this study to look at if the study drug, osimertinib, is safe and will work on patients with non-small cell lung cancer (NSCLC).
Who Can Participate in the Study?
Adults who have confirmed non-small cell lung cancer with EGFR Mutations
What is Involved?
If you choose to join this study, you will:
-Take Osimbertinib (80mg) by mouth 
- Have routine eye exams and EKGs 
- Have blood samples and possibly a small piece of tissue removed from your lung to see what type of lung cancer cells you have
- Have other tests, exams, and procedures for study purposes and your standard of care
- Be in the study for up to 24 months after the start of study drug or until your condition worsens or you have unbearable side effects
Participating Institutions:
  • Duke University Health System : Thoracic Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

DF/HCC: 17-540 (Non-Small Cell Lung Cancer)
Principal Investigator: Stinchcombe, Thomas
Protocol Number: PRO00090252

Age Group: Adult
Scope: National

Phase: II (Cancer Control)
Disease Site: Lung

Contact: DCI Clinical Research Team, Thoracic Oncology
Email:

What is the Condition Being Studied?
Non-Small Cell Lung Cancer (NSCLC) 
What is the Purpose of this Study?
We are doing this study to find out if a combination of the study drugs, Osimertinib and Selumetinib, are safe and will work in treating Non-Small Cell Lung Cancer (NSCLC) with a gene mutation.
Who Can Participate in the Study?
Adults who have stage IV NSCLC with EGFR mutation.
What is Involved?
If you choose to join this study, you will: 
- Get study drugs Osimertinib and Selumetinib
-- You will take Osimertinib once a day every day and Selumetinib twice a day for 4 days
- Have routine eye exams
- Have blood samples and possibly a small piece of tissue removed from your lung to see what type of lung cancer cells you have
- Have other tests, exams, and procedures for study purposes and your standard of care
- Be in the study until your condition worsens or you have unbearable side effects
Participating Institutions:
  • Duke University Health System : Thoracic Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

TOP 1705- Non-Small Lung Cancer
Principal Investigator: Clarke, Jeffrey
Protocol Number: PRO00092210

Age Group: Adult
Scope:

Phase: II
Disease Site: Lung

Contact: DCI Clinical Research Team, Thoracic Oncology
Email:

What is the Condition Being Studied?
Non Small Cell Lung Cancer (NSCLC)
What is the Purpose of this Study?
We are doing this study to find out how safe the study drug combination of Nivolumab, Ipilimumab, and Paclitaxel is for people with non small cell lung cancer and if this combination will work.
Who Can Participate in the Study?
Adults 18 years or older with Stage IV or recurrent NSCLC with no prior treatment
What is Involved?
If you choose to join this study, you will:
- Get chemotherapy and immunotherapy
- Have blood samples and possibly a small piece of tissue removed from your lung to see what type of lung cancer cells you have
- Have other tests, exams, and procedures for study purposes and your standard of care
- Be in the study for up to 24 months after the start of study drug or until your condition worsens or you have unbearable side effects
Participating Institutions:
  • Duke Center for Living/Sarah Stedman Nutrition : Thoracic Oncology DCI Clinical Research Team
  • Duke Primary Care : Thoracic Oncology DCI Clinical Research Team
  • Duke Private Diagnostic Clinic (PDC) : Thoracic Oncology DCI Clinical Research Team
  • Duke University Health System : Thoracic Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

UM1 10107 Anetumab ravtansine + Pembrolizumab in Pleural Mesothelioma
Principal Investigator: Abbruzzese, James
Protocol Number: PRO00092358

Age Group: Adult
Scope: National

Phase: I (Cancer Control)
Disease Site: Lung

Contact: DCI Clinical Research Team, Thoracic Oncology
Email:

What is the Condition Being Studied?
Mesothelioma which has grown or has returned after initial treatment with chemotherapies
What is the Purpose of this Study?
We are doing this study to test the safety of the study drug Anetumab ravtansine when it is given with MK-3475 (pembrolizumab) at different doses to find out what effect, if any, it has on people. 
Who Can Participate in the Study?
Adults with malignant pleural mesothelioma who have received platinum based chemotherapy
What is Involved?
The study is divided into two parts.
-- Part 1 is looking for the best dose of Anetumab ravtansine
-- Part 2 will look at the activity and safety of Pemrolizumab with and without Anetumab ravtansine

If you join this study:
In part 1, the first group of study patients will receive the most commonly used doses of both drugs. 
-- If the study drugs cause serious side effects, the second group of study patients will receive a lower dose of Anetumab ravtansine. 
-- If the study drugs do not cause serious side effects, these doses will be used for the second part of the study and at that time, the first part of the study will be stopped. 

In part 2: you will be randomly (like flipping a coin) assigned by a computer to be in either Group 1 or 2. 
Group 1 will receive anetumab ravtansine and MK-3475 (pembrolizumab) 
Group 2 will receive only MK-3475 (pembrolizumab).

Participating Institutions:
  • Duke University Health System : Thoracic Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov